Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations;), Gujarat Themis Biosyn has informed that the company (GTBL) has completed the acquisition of MicroBiopharm Japan Co., (MBJ), Japan, through its wholly owned subsidiary, Themis Biosyn Japan (TBJ), by making an investment of INR 475 Crores towards capital contribution and INR 745 Crores by way of loan in TBJ. In this regard GTBL has entered into a Loan agreement with TBJ for an amount upto INR 800 Crores on the terms as may be agreed. Details of the agreement are given in annexure 1 attached. A Press release in this respect is attached.
The above information is a part of company’s filings submitted to BSE.
